What does this study add? This analysis shows that treatment with sarilumab with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) resulted in statistically or nominally significant improvements in PROs in patients with an inadequate response or intolerance to tumour necrosis factor-α inhibitors (TNF-IR) in moderate-to-severely active RA.
← all excerpts
Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
1
—
—